Project	Intended use for Impact	Impact statement:	Headline (<20 words, < 30s if
	statement		read outloud):
ME Therapeutics	Both	Colon cancer patients respond weakly to available immunotherapy drugs and have poor outcomes. The reason for this is colon cancers likely develop multiple mechanisms to evade the immune system and therefore, a two-pronged attack is necessary to generate productive anti-cancer responses. First-generation immunotherapy drugs enhance the function of cancer-killing T cells but leave immunosuppressive cells unchecked. Consequently, we will improve anti-tumour responses using first-generation immunotherapy drugs in combination with our therapeutic antibodies that block the development of immunosuppressive cells.	Second- generation immunotherap y synergizes with current treatments to improve survival for colon cancer patients